{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:09:16Z","timestamp":1790363356091,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1722665"],"award-info":[{"award-number":["1722665"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jval.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T04:04:57Z","timestamp":1710389097000},"page":"918-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation"],"prefix":"10.1016","volume":"27","author":[{"given":"Huaiyang","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Hiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvier","family":"Serumondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueran","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Adee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallican N.","family":"Rwibasira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2024.03.005_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/gut.2003.026393","article-title":"Fibrosis progression in chronic hepatitis C virus infection","volume":"53","author":"McCaughan","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jval.2024.03.005_bib3","series-title":"Sleisenger and Fordtran\u2019s Gastrointestinal and Liver Disease E-book: Pathophysiology, Diagnosis, Management","author":"Feldman","year":"2020"},{"issue":"21","key":"10.1016\/j.jval.2024.03.005_bib4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10207","key":"10.1016\/j.jval.2024.03.005_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jval.2024.03.005_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.03.005_bib9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12879-019-4322-7","article-title":"Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program","volume":"19","author":"Makuza","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.jval.2024.03.005_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: a landmark in sub-Saharan Africa","volume":"70","author":"Umutesi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jval.2024.03.005_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2471\/BLT.16.183772","article-title":"Controlling hepatitis C in Rwanda: a framework for a national response","volume":"96","author":"Mbituyumuremyi","year":"2018","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jval.2024.03.005_bib15","author":"Serumondo"},{"issue":"4","key":"10.1016\/j.jval.2024.03.005_bib16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jval.2024.03.005_bib17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals","volume":"64","author":"Chhatwal","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jval.2024.03.005_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3613","article-title":"Assessment of the feasibility and cost of hepatitis C elimination in Pakistan","volume":"2","author":"Chhatwal","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jval.2024.03.005_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cld.1109","article-title":"A\u00a0tool to inform hepatitis C elimination: a case for hepatitis C elimination in China","volume":"17","author":"Adee","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jval.2024.03.005_bib20","unstructured":"Policy OoRaD. Soc Sec Programs Throughout World Afr. 2019:20192023."},{"issue":"1","key":"10.1016\/j.jval.2024.03.005_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12916-015-0443-z","article-title":"Improving health outcomes through concurrent HIV program scale-up and health system development in Rwanda: 20 years of experience","volume":"13","author":"Nsanzimana","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.jval.2024.03.005_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.14204","article-title":"Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-na\u00efve, genotype 1 hepatitis C infected patients","volume":"46","author":"Curry","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jval.2024.03.005_bib25","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1053\/j.gastro.2017.01.017","article-title":"Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection","volume":"152","author":"Gane","year":"2017","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10.1016\/j.jval.2024.03.005_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jval.2024.03.005_bib28","series-title":"CHOosing Interventions That Are Cost Effective","year":"2022"},{"issue":"2","key":"10.1016\/j.jval.2024.03.005_bib29","article-title":"Production losses associated with premature mortality in 28 European Union countries","volume":"9","author":"Lyszczarz","year":"2019","journal-title":"J\u00a0Glob Health"},{"key":"10.1016\/j.jval.2024.03.005_bib32","first-page":"68","article-title":"Expanding molecular diagnostic capacity for COVID-19 in Ethiopia: operational implications, challenges and lessons learnt","volume":"38","author":"Kebede","year":"2021","journal-title":"Pan Afr Med J"},{"issue":"12","key":"10.1016\/j.jval.2024.03.005_bib33","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.jval.2024.03.005_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Observatory","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jval.2024.03.005_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jval.2024.03.005_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.jval.2024.03.005_bib37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"Waked","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2024.03.005_bib38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40121-022-00631-x","article-title":"Pursuing elimination of hepatitis C in Egypt: cost-effectiveness and economic evaluation of a country-wide program","volume":"11","author":"Schwander","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:51:18Z","timestamp":1762365078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1098301524001190"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.03.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}